Radius Health

232 articles with Radius Health

• Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

  10/20/2021

  Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021.

• Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis

  10/18/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis.

• 

  Novel CAR T Therapies Help Celyad's CMO Bring Hope to Fearful Patients

  9/29/2021

  Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.

• Radius Health Business Update - July 27, 2021

  7/27/2021

  New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.

• 

  Clinical Catch-Up: July 19-23

  7/26/2021

  It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.

• Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

  7/22/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a synthetic cannabidiol oral solution.

• Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021

  7/20/2021

  Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021.

• Radius Health, Inc.: First Quarter 2021 Results

  5/7/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2021.

• Radius Health Business Update

  4/22/2021

  Radius Health, Inc., provided the following business update. The Company’s first quarter 2021 earnings will take place on Friday, May 7 at 8:30am EST.

• Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021

  4/20/2021

  Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021.

• Radius Health Provides Update on Abaloparatide

  3/24/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided an update on the abaloparatide asset including regulatory progress as well as U.S. commercial activity.

• Radius Health, Inc. Announces $175 Million Financing Transaction

  3/3/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan, which includes a cashless conversion of $25 million in existing term loans, and a $25 million revolving credit facility

• Radius Health, Inc.: Fourth Quarter and Full Year Results - Feb 25, 2021

  2/25/2021

  Radius Health, Inc., reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results.

• Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference

  2/17/2021

  Radius Health, Inc., announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.

• Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021

  2/16/2021

  Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

• Radius Health, Inc. Announces Acquisition of Orphan Disease Program

  1/6/2021

  RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases

• Radius Health, Inc. Provides Business Update

  12/15/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020.

• Radius Health, Inc.: Third Quarter 2020 Operating Results

  11/5/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2020, and provided a business update.

• Radius Health, Inc.: Progress Since May 2020

  10/21/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020.

• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.